Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women, 18 years old and above~* Diabetes mellitus type 2 patients who has failed an oral hypoglycemic drug products, insulin-naive, disease duration of at least 6 months, inadequate glycemic control (HbA1c \> 7.0 %)~* BMI ranged from 19 - 35 kg/m2~* Consent from patients of childbearing potential to use contraception method throughout the study~* Signed informed consent form~Exclusion Criteria:~* History of diabetic ketoacidosis more than 2 times in the past 1 year~* History of pancreatectomy~* Estimated glomerular filtration rate \<30 mL/min~* Positive ZnT8 Antibody~* Treatment with glucocorticoids, immunodepressant or cytostatics in 60 days before study.~* Any malignant disease, including in medical history~* Drugs and alcohol abuse, including in medical history~* Hipersensitivity to insulin glargine or any excipient of the drugs from medical history~* Mental disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Glargine Ezelin (Type: EXPERIMENTAL): Drug product Insulin Glargine, Ezelin 100 U/mL (PT Kalbe Farma, Tbk)
- Insulin Glargine Lantus (Type: ACTIVE_COMPARATOR): Insulin Glargine Pen Injector \[Lantus\]

Based on this trial design, predict the completion outcome and termination type (if applicable).